ATE318835T1 - Schutz endogener, therapeutisch aktiver peptide vor peptidaseaktivität durch konjugation an blutbestandteile - Google Patents

Schutz endogener, therapeutisch aktiver peptide vor peptidaseaktivität durch konjugation an blutbestandteile

Info

Publication number
ATE318835T1
ATE318835T1 AT00936023T AT00936023T ATE318835T1 AT E318835 T1 ATE318835 T1 AT E318835T1 AT 00936023 T AT00936023 T AT 00936023T AT 00936023 T AT00936023 T AT 00936023T AT E318835 T1 ATE318835 T1 AT E318835T1
Authority
AT
Austria
Prior art keywords
peptide
terminus
peptidase activity
amino acid
protection
Prior art date
Application number
AT00936023T
Other languages
English (en)
Inventor
Dominique P Bridon
Alan M Ezrin
Peter G Milner
Darren L Holmes
Karen Thibaudeau
Original Assignee
Conjuchem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conjuchem Inc filed Critical Conjuchem Inc
Application granted granted Critical
Publication of ATE318835T1 publication Critical patent/ATE318835T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/645—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/465—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from birds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT00936023T 1999-05-17 2000-05-17 Schutz endogener, therapeutisch aktiver peptide vor peptidaseaktivität durch konjugation an blutbestandteile ATE318835T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13440699P 1999-05-17 1999-05-17
US15340699P 1999-09-10 1999-09-10
US15978399P 1999-10-15 1999-10-15

Publications (1)

Publication Number Publication Date
ATE318835T1 true ATE318835T1 (de) 2006-03-15

Family

ID=27384581

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00936023T ATE318835T1 (de) 1999-05-17 2000-05-17 Schutz endogener, therapeutisch aktiver peptide vor peptidaseaktivität durch konjugation an blutbestandteile

Country Status (11)

Country Link
EP (5) EP2100901A1 (de)
JP (6) JP4217004B2 (de)
AT (1) ATE318835T1 (de)
AU (1) AU765753B2 (de)
CA (4) CA2505617A1 (de)
DE (1) DE60026300T2 (de)
DK (1) DK1105409T3 (de)
ES (1) ES2257298T3 (de)
PT (1) PT1105409E (de)
SI (1) SI1105409T1 (de)
WO (1) WO2000069900A2 (de)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2209885T3 (es) 1999-05-17 2004-07-01 Conjuchem, Inc. Peptidos insulinotropicos de larga duracion.
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US20030054988A1 (en) * 2000-11-02 2003-03-20 Weidong-Richard Ji Modified plasminogen related peptide fragments and their use as angiogenesis inhibitors
CA2435563A1 (en) 2001-02-02 2002-08-15 Conjuchem Inc. Long lasting growth hormone releasing factor derivatives
EP1360202B1 (de) * 2001-02-16 2008-05-21 ConjuChem Biotechnologies Inc. Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
EP1573024A4 (de) 2001-04-10 2007-08-29 Agensys Inc Nukleinsäuren und diesen entprechende, für die behandlung und den nachweis verschiedener krebserkrankungen geeignete proteine
EP2228387A2 (de) * 2001-04-18 2010-09-15 The Open University Polypeptide, abgeleitet vom "Amyloid Precursor Peptide (AAP)" und ihre Verwendungen
US7491702B2 (en) 2001-04-18 2009-02-17 The Open University Polypeptides related to amyloid precursor protein, pharmaceutical compositions thereof, and methods of treatment using the same
JP2004536062A (ja) * 2001-05-17 2004-12-02 セレメディックス，インク． 反応性酸素種およびフリーラジカルの効力を中和するためのペプチド化合物
US20050026165A1 (en) 2001-05-31 2005-02-03 Cindy Orser Detection of conformationally altered proteins and prions
MXPA03011000A (es) 2001-05-31 2004-02-27 Arete Associates Metodo de sensor de proteinas deformadas.
WO2002096935A2 (en) 2001-05-31 2002-12-05 Conjuchem, Inc. Long lasting fusion peptide inhibitors for hiv infection
US7544653B2 (en) * 2001-10-18 2009-06-09 Zlatko Ademovic Additive cytoprotective effects of two bioactive regions of pro-opiomelanocortin hormone
US6822073B2 (en) * 2001-12-20 2004-11-23 Kimberly-Clark Worldwide, Inc. Modular peptide-based reagent
JPWO2003078460A1 (ja) * 2002-03-19 2005-07-14 株式会社オンコレックス ペプチド、該ペプチドを含有する医薬組成物及び癌治療用医薬組成物
JP2004008027A (ja) * 2002-06-04 2004-01-15 Japan Science & Technology Corp ｃＡＭＰの産生活性を有する新規ペプチド
WO2004011595A2 (fr) * 2002-07-26 2004-02-05 Institut Pasteur Vecteurs destines au transfert de molecules d'interet dans des cellules cibles
EP1530588A2 (de) * 2002-07-31 2005-05-18 Conjuchem, Inc. Lang wirkende natriuretische peptid derivate
CN1327897C (zh) * 2002-09-24 2007-07-25 重庆前沿生物技术有限公司 Hiv感染的肽衍生物融合抑制剂
US7378495B2 (en) * 2002-10-21 2008-05-27 Pevion Biotech, Ltd. PTH-rP related peptide cancer therapeutics
AU2003290563A1 (en) * 2002-10-31 2004-05-25 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
WO2004043383A2 (en) 2002-11-07 2004-05-27 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services A new target for angiogenesis and anti-angiogenesis therapy
US7648962B2 (en) 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
AU2003297583B2 (en) * 2002-11-26 2010-01-14 Biocon, Ltd Modified naturetic compounds, conjugates, and uses thereof
JP3974619B2 (ja) * 2003-01-10 2007-09-12 株式会社新潟ティーエルオー 遺伝子治療用ベクター及び該遺伝子治療用ベクターを投与された哺乳動物中又は培養細胞中の目的タンパク質の定量方法
AU2003210714A1 (en) * 2003-01-29 2004-08-30 Advanced Research And Technology Institute, Inc. Immunoregulating compounds and an associated method
DE10316583A1 (de) 2003-04-10 2004-10-28 B.R.A.H.M.S Aktiengesellschaft Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung
US20070082363A1 (en) * 2003-04-25 2007-04-12 Lydie Bougueleret Secreted polypeptide species reduced cardiovascular disorders
EP1648933B1 (de) * 2003-07-25 2009-06-17 ConjuChem Biotechnologies Inc. Insulinderivative mit langanhaltender wirkung und verfahren zu deren herstellung
EP1789440A4 (de) * 2004-02-11 2008-03-12 Amylin Pharmaceuticals Inc Pankreas-polypeptidfamilienmotive und diese enthaltende polypeptide
JPWO2005090399A1 (ja) * 2004-03-24 2008-05-08 財団法人岐阜県研究開発財団 各種細胞の増殖・分化を認識する抗体、その抗体を用いた増殖・分化の評価方法
ES2524309T3 (es) * 2004-04-20 2014-12-05 Sphingotec Gmbh Utilización de precursores de taquicininas y/o de sus fragmentos en diagnóstico médico
ES2365023T3 (es) 2004-04-21 2011-09-20 Enobia Pharma Inc. Conjugados de administración ósea y método de uso de los mismos para dirigir proteínas a hueso.
EP2293079B1 (de) * 2004-05-13 2013-08-14 B.R.A.H.M.S GmbH Verwendung von Enkephalin-Vorläufern und/oder Fragmenten davon in der medizinischen Diagnostik
AU2012202855B2 (en) * 2004-09-03 2015-02-26 Philipps-Universitat Marburg GLP-1 and exendin related invention
DE102004043153B4 (de) * 2004-09-03 2013-11-21 Philipps-Universität Marburg Erfindung betreffend GLP-1 und Exendin
US7704955B2 (en) 2004-11-24 2010-04-27 Neopro Pain, Inc. Methods and compositions for modulating conditions in both mammals and plants
JP4720175B2 (ja) * 2004-12-15 2011-07-13 富士ゼロックス株式会社 マレイミジル基含有材料およびその製造方法
DE102005003687A1 (de) 2005-01-26 2006-07-27 Sphingo Tec Gmbh Immunoassay zur Bestimmung der Freisetzung von Neurotensin in die Zirkulation
AU2006214463B2 (en) 2005-02-15 2012-08-30 Presympto, Inc. Method for detecting misfolded proteins and prions
WO2006108686A2 (en) * 2005-04-14 2006-10-19 Aic Bnp agonists
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
WO2006121869A2 (en) * 2005-05-05 2006-11-16 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating mood and anxiety disorders
US20100021480A1 (en) * 2005-10-27 2010-01-28 Peptron Co., Ltd Bioactive substance-blood protein conjugate and stabilization of a bioactive substance using the same
US7557088B2 (en) 2006-03-28 2009-07-07 Neopro Labs, Llc Methods and compositions for treating conditions
WO2008047241A2 (en) 2006-10-16 2008-04-24 Conjuchem Biotechnologies Inc. Modified corticotropin releasing factor peptides and uses thereof
WO2008052043A2 (en) * 2006-10-24 2008-05-02 Cogenesys, Inc. Opioid receptor agonist fusion proteins
AU2007343796A1 (en) 2006-10-25 2008-07-24 Amgen Inc. Toxin peptide therapeutic agents
AU2008232709C1 (en) 2007-03-28 2015-01-15 President And Fellows Of Harvard College Stitched polypeptides
CA2683288A1 (en) 2007-05-17 2008-11-27 Neopro Labs, Llc Crystalline and amorphous forms of peptide
MX2009012609A (es) 2007-05-22 2009-12-07 Amgen Inc Composiciones y metodos para producir proteinas de fusion bioactivas.
WO2009023125A1 (en) * 2007-08-14 2009-02-19 The Board Of Trustees Of The Leland Stanford Junior University Neuronostatin and its uses
RU2010114017A (ru) * 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) Терапевтическое применение натрийуретического пептида в-типа и гормона роста человека 1-43
AU2008297535A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of fibronectin fragment (196-203 ) as a therapeutic agent
CA2698768A1 (en) * 2007-09-11 2009-04-02 Dorian Bevec Use of a peptide as a therapeutic agent
US20100323950A1 (en) * 2007-09-11 2010-12-23 Dorian Bevec Use of beta-melanotropin as a therapeutic agent, eg for the treatment of aids or alzheimer
RU2010136023A (ru) 2008-02-01 2012-03-10 Асцендис Фарма Ас (Dk) Пролекарство, содержащее саморасщепляемый линкер
WO2009121884A1 (en) 2008-04-01 2009-10-08 Novo Nordisk A/S Insulin albumin conjugates
WO2009142727A2 (en) * 2008-05-19 2009-11-26 Vasogenix Pharmaceuticals, Inc. Sequence modified calcitonin gene related peptides (cgrp)
KR20110122134A (ko) 2009-02-25 2011-11-09 머크 샤프 앤드 돔 코포레이션 글리코공학처리된 효모 피키아 파스토리스에서 갈락토스 동화 경로의 대사 공학
AU2010279076B2 (en) * 2009-07-29 2014-09-25 Daiichi Sankyo Company,Limited Motilin-like peptide compound having transmucosal absorbability imparted thereto
SG178193A1 (en) 2009-07-31 2012-03-29 Sanofi Aventis Deutschland Prodrugs comprising an insulin linker conjugate
RU2556340C2 (ru) 2009-07-31 2015-07-10 Санофи-Авентис Дойчланд Гмбх Композиция инсулина длительного действия
WO2011050471A1 (en) * 2009-10-28 2011-05-05 University Of Manitoba Yellow pea seed protein-derived peptides
KR101930961B1 (ko) 2010-02-24 2018-12-19 머크 샤프 앤드 돔 코포레이션 피키아 파스토리스에서 생산된 치료 당단백질 상의 ｎ-글리코실화 부위 점유를 증가시키는 방법
RU2559320C2 (ru) * 2010-03-26 2015-08-10 Ново Нордиск А/С Новые аналоги глюкагона
SI2603600T1 (sl) 2010-08-13 2019-04-30 Aileron Therapeutics, Inc. Peptidomimetični makrocikli
EP2438930A1 (de) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrug mit einem exendinbindenden Konjugat
EP2658979B1 (de) 2010-12-27 2018-02-14 Alexion Pharmaceuticals, Inc. Zusammensetzungen mit natriuretischen peptiden und verwendungsverfahren dafür
CA2849673A1 (en) 2011-09-23 2013-03-28 Novo Nordisk A/S Novel glucagon analogues
TWI643868B (zh) 2011-10-18 2018-12-11 艾利倫治療公司 擬肽巨環化合物
US8987414B2 (en) 2012-02-15 2015-03-24 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
KR102112373B1 (ko) 2012-02-15 2020-05-18 에일러론 테라퓨틱스 인코포레이티드 펩티드모방체 마크로사이클
JP2013179884A (ja) * 2012-03-01 2013-09-12 Mitsubishi Rayon Co Ltd メラニンカスケードに関与する成分を評価するための核酸マイクロアレイ及びメラニンカスケードに関与する成分の評価方法
KR20220051197A (ko) 2012-05-17 2022-04-26 익스텐드 바이오사이언시즈, 인크. 개선된 약물 전달용 캐리어
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
AU2013337388B2 (en) 2012-11-01 2018-08-02 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
MX362275B (es) 2013-04-18 2019-01-10 Novo Nordisk As Co-agonista de peptido similar a glucagon tipo 1 (glp-1) receptor de glucagon de larga duracion, estables para uso medico.
PT3016671T (pt) * 2013-07-04 2021-12-02 Univ Barcelona Péptidos ativamente transportados e resistentes à protease como transportes bbb e construtos de transporte de carga
EP3094643B1 (de) * 2014-01-15 2018-10-17 Fyziologicky ustav Akademie ved Ceske republiky, v.v.i. Lipophile peptide zur senkung des blutglucosespiegels
WO2015185640A1 (en) 2014-06-04 2015-12-10 Novo Nordisk A/S Glp-1/glucagon receptor co-agonists for medical use
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
WO2016049359A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
EP3220961B1 (de) 2014-10-22 2023-07-05 Extend Biosciences, Inc. Therapeutische vitamin-d-konjugate
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
US10449236B2 (en) 2014-12-05 2019-10-22 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
CA2973883A1 (en) 2015-01-28 2016-08-04 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
EP3197479B1 (de) * 2015-02-22 2019-06-26 Omnix Medical Ltd. Antimikrobielle peptide
MX2017011834A (es) 2015-03-20 2018-04-11 Aileron Therapeutics Inc Macrociclos peptidomimeticos y usos de los mismos.
US11352612B2 (en) 2015-08-17 2022-06-07 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
WO2017058822A1 (en) 2015-09-28 2017-04-06 Alexion Pharmaceuticals, Inc. Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia
EP3368062A4 (de) 2015-10-30 2019-07-03 Alexion Pharmaceuticals, Inc. Verfahren zur behandlung von craniosynostose bei einem patienten
US11530243B2 (en) * 2016-02-18 2022-12-20 Veiove Animal Health Inc. Non-cleavable substance P conjugates and methods of use thereof
WO2017155569A1 (en) 2016-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
CA3019726A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Treating muscle weakness with alkaline phosphatases
WO2017173395A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
EP3500289B1 (de) 2016-08-18 2024-10-09 Alexion Pharmaceuticals, Inc. Asfotase alfa zur behandlung von tracheobronchomalazie
SG11201907914QA (en) 2017-03-01 2019-09-27 Chengdu Huitai Biomedicine Co Ltd Polypeptide, polypeptide fragment, derivative thereof, and applications thereof
CN110719786A (zh) 2017-03-31 2020-01-21 阿雷克森制药公司 用于治疗成人和青少年的低磷酸酯酶症(hpp)的方法
WO2018221745A1 (ja) * 2017-06-02 2018-12-06 株式会社Ｌｓｉメディエンス 生体試料中からの標的タンパク質の抽出方法および標的タンパク質の分析方法
CN109503700A (zh) * 2017-09-14 2019-03-22 南京安吉生物科技有限公司 马来酰亚胺基团修饰的血管生成抑制剂hm-1及其应用
EP3717508A1 (de) 2017-12-01 2020-10-07 The University of Copenhagen Peptidhormon mit einem oder mehreren o-glykanen
EP3773684A1 (de) 2018-03-30 2021-02-17 Alexion Pharmaceuticals, Inc. Herstellung von glycoproteinen
WO2019197313A1 (en) 2018-04-09 2019-10-17 Svar Life Science Ab Glucagon Assay
IT202000007720A1 (it) * 2020-04-10 2021-10-10 Alessandra Marconi Peptidi e loro usi
JP2023550784A (ja) * 2020-11-25 2023-12-05 プロリンクス エルエルシー Ｃ－ナトリウム利尿ペプチドの徐放性ヒドロゲルコンジュゲート
CA3173631A1 (en) 2021-02-12 2022-08-18 Walter C. Voegtli Alkaline phosphatase polypeptides and methods of use thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3719667A (en) 1970-08-24 1973-03-06 Lilly Co Eli Epimerization of 6-acylamido and 6-imido penicillin sulfoxide esters
US3840556A (en) 1971-05-28 1974-10-08 Lilly Co Eli Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby
BE795238A (fr) * 1972-02-09 1973-08-09 Schering Ag Derives d'insuline reticules de maniere intramoleculaire, leur procede de preparation et leur utilisation
US4462941A (en) 1982-06-10 1984-07-31 The Regents Of The University Of California Dynorphin amide analogs
DE3604868A1 (de) * 1986-02-15 1987-08-20 Behringwerke Ag Insulinderivate, verfahren zu ihrer herstellung und ihre verwendung
DD252539A1 (de) * 1986-09-17 1987-12-23 Berlin Chemie Veb Verfahren zur oralen anwendung biologisch aktiver peptide mit verzoegerter wirkung
US5612034A (en) 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
US5422339A (en) * 1991-03-19 1995-06-06 Joslin Diabetes Center, Inc. Peptides having insulin autoantibody but not insulin receptor binding capacity
WO1992017492A1 (en) 1991-04-05 1992-10-15 Genentech, Inc. PLATELET AGGREGATION INHIBITORS HAVING HIGH SPECIFICITY FOR GP IIbIII¿a?
HUT70160A (en) 1992-06-12 1995-09-28 Des Tyr Dynorphin Partnership Process for producing des-tyr dynorphin analogues
EP0602290B1 (de) * 1992-12-04 1999-08-25 ConjuChem, Inc. Antikörper-konjugiertes-Hepatitis B-Oberflächenantigen und dessen Verwendung
US5446128A (en) * 1993-06-18 1995-08-29 The Board Of Trustees Of The University Of Illinois Alpha-helix mimetics and methods relating thereto
US5580853A (en) * 1994-03-22 1996-12-03 New England Deaconess Hospital Modified polypeptides with increased biological activity
AU7637394A (en) 1994-08-26 1996-03-22 Avram Goldstein Analgesic method with dynorphin analogues truncated at the n-terminus
US5654276A (en) * 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
CA2279836A1 (en) * 1997-02-05 1998-08-13 1149336 Ontario Inc. Polynucleotides encoding proexendin, and methods and uses thereof
EP1056474B1 (de) * 1997-11-07 2002-06-12 ConjuChem, Inc. Affinitätsmarkierer für menschliches serum albumin
WO1999024076A2 (en) * 1997-11-07 1999-05-20 Conjuchem, Inc. Salicylate derivatized therapeutic and diagnostic agents
CA2321026A1 (en) * 1998-03-09 1999-09-16 Zealand Pharmaceuticals A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
IL133053A0 (en) * 1998-03-23 2001-03-19 Conjuchem Inc Local delivery of long lasting therapeutic agents

Also Published As

Publication number Publication date
CA2505617A1 (en) 2000-11-23
EP1105409A2 (de) 2001-06-13
SI1105409T1 (sl) 2006-06-30
CA2373680C (en) 2008-07-29
ES2257298T3 (es) 2006-08-01
JP4221392B2 (ja) 2009-02-12
CA2499211A1 (en) 2000-11-23
JP4219339B2 (ja) 2009-02-04
DE60026300T2 (de) 2006-11-16
CA2623458A1 (en) 2000-11-23
DK1105409T3 (da) 2006-07-03
JP2005239736A (ja) 2005-09-08
JP4217004B2 (ja) 2009-01-28
EP1105409B1 (de) 2006-03-01
EP1598365A1 (de) 2005-11-23
EP1623994A2 (de) 2006-02-08
EP2100901A1 (de) 2009-09-16
AU5139300A (en) 2000-12-05
JP2008150384A (ja) 2008-07-03
AU765753B2 (en) 2003-09-25
JP2005263807A (ja) 2005-09-29
JP2009079048A (ja) 2009-04-16
JP2003508350A (ja) 2003-03-04
WO2000069900A9 (en) 2002-07-04
CA2373680A1 (en) 2000-11-23
EP1591453A1 (de) 2005-11-02
DE60026300D1 (de) 2006-04-27
WO2000069900A2 (en) 2000-11-23
PT1105409E (pt) 2006-07-31
JP2010168384A (ja) 2010-08-05
WO2000069900A3 (en) 2001-02-15
EP1623994A3 (de) 2008-07-16

Similar Documents

Publication Publication Date Title
DE60026300D1 (de) Schutz endogener, therapeutisch aktiver peptide vor peptidaseaktivität durch konjugation an blutbestandteile
Mentlein Proline residues in the maturation and degradation of peptide hormones and neuropeptides
NO20015584D0 (no) Lantidsvarende insulintrofiske peptider
WO1996000503B1 (en) Novel peptides
EA199700239A1 (ru) Ингибиторы тромбина, основанные на аминокислотной последовательности гирудина
EP0994724A4 (de) Verfahren und zusammensetzungen zur behinderung der vervielfältigung von hiv-1
ATE399177T1 (de) Derivate therapeutischer peptide
RO80806A (ro) Procedeu pentru obtinerea enzimatica a peptidelor
ATE165836T1 (de) Peptide als arzneimittel
CA2420350A1 (en) Membrane penetrating peptides and uses thereof
ATE297219T1 (de) Antikörper als arzneimittel gegen lymphocytische tumore (ausschliesslich myelome)
NZ336116A (en) Diagnostic agent comprising an amino acid or peptide containing at least one 13C or 14C for pancreatic exocrine function
MX9702152A (es) Clonacion de una aminopeptidasa de membrana, dependiente de la insulina, a partir de vesiculas de glut-4.
NO20025064D0 (no) RGO koblet til peptider
NO964561L (no) Tri-, tetra-, penta-, og polypeptider, og bruken av disse som antidepressiv agent
CA2373252A1 (en) Long lasting anti-angiogenic peptides
US4835253A (en) Specific inhibitors of tissue kallikrein
TW200602353A (en) Modified secretin and method of synthesizing thereof
Yoshikawa et al. Biologically active peptides derived from food and blood proteins
IL150045A0 (en) Compositions and methods for detecting stress-inducible proteins
Su et al. Investigation into the intestinal metabolism of [D-Ala1] peptide T amide: implication for oral drug delivery
DE69827880D1 (de) Iga1-protease fragment als trägerpeptid
WO2002099379A3 (en) Breast homing peptides and methods of identifying same using aminopeptidase p
NZ211403A (en) Renin-inhibiting peptides and pharmaceutical compositions
WO2001005420A8 (en) SMALL PEPTIDES AND METHODS FOR DOWNREGULATION OF IgE

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1105409

Country of ref document: EP

EEIH Change in the person of patent owner